Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

Area of Science:

• Cardiovascular Research
• Vascular Biology
• Biomedical Science

Background:

• The role of osteoprotegerin (OPG) in vascular disease remains debated.
• Observational studies link higher OPG levels to severe coronary artery disease, atherosclerosis, and vascular calcification.
• Murine genetic and treatment studies suggest OPG may protect against vascular calcification.

Purpose of the Study:

• To investigate whether osteoprotegerin (OPG) induces or prevents vascular disease.
• To elucidate the specific role of OPG in the development of atherosclerosis and vascular calcification.

Main Methods:

• Atherogenic diet-fed low-density lipoprotein receptor-deficient (ldlr(-/-)) mice were treated with recombinant OPG (Fc-OPG) or vehicle for 5 months.
• Evaluated atherosclerosis progression, lesion size, vascular cytokines, plasma cholesterol, and tissue markers of mineralization (osteocalcin).

Main Results:

• Fc-OPG treatment significantly reduced the calcified lesion area in mice.
• OPG treatment did not affect atherosclerotic lesion size, number, vascular cytokines, or plasma cholesterol.
• Vehicle-treated mice showed progressive atherosclerosis with increased plasma OPG levels and some calcified lesions.

Conclusions:

• Osteoprotegerin (OPG) acts as an inhibitor of vascular calcification.
• OPG serves as a marker, not a mediator, of atherosclerosis progression.
• These findings support a protective role for OPG in preventing vascular mineralization.